PLRZHealthcare · BiotechnologyPLRZ Stock Forecast: Polyrizon Ltd. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 16 of 100 as at 1 Aug 2026 — in the weakest quartile.
PLRZ stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Polyrizon Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (87): Smaller than most of the companies we track.
Value (8): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own Polyrizon Ltd. — and when they’d sell — is the membership.
PLRZ stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on PLRZ, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PLRZ analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Polyrizon Ltd. (PLRZ) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.8×
- EV / EBITDA
- −1.0×
Cheaper than 77% of US stocks
Cheaper than 68% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −25.4%
- Return on assets
- −28.9%
- Dividend yield
- —
Higher than 29% of US stocks
Higher than 14% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
PLRZ vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PLRZ appears on the weeks it earns a place.
Frequently asked questions about PLRZ stock
How does Ticker Nerd's model rank PLRZ?
As at 1 Aug 2026, Polyrizon Ltd. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (87 of 100).
What is the PLRZ stock forecast for 2030?
No analyst covering Polyrizon Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PLRZ are extrapolating price history, which says nothing about the business.
How has PLRZ stock performed over the past year?
Polyrizon Ltd. returned +21.4% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Polyrizon Ltd. do?
Polyrizon Ltd is a clinical development stage biotechnology company focused on innovative nasal hydrogel technologies for respiratory health and protective applications. The company develops medical device hydrogels delivered as nasal sprays that form a thin, bioadhesive barrier in the nasal cavity, designed to act as a “biological mask” against a broad range of airborne viruses, allergens, and other environmental particles.
About Polyrizon Ltd.
Polyrizon Ltd is a clinical development stage biotechnology company focused on innovative nasal hydrogel technologies for respiratory health and protective applications. The company develops medical device hydrogels delivered as nasal sprays that form a thin, bioadhesive barrier in the nasal cavity, designed to act as a “biological mask” against a broad range of airborne viruses, allergens, and other environmental particles. Its core Capture and Contain platform uses naturally occurring building blocks to create a shield that helps limit contact between inhaled agents and nasal epithelial tissue. In parallel, Polyrizon Ltd is advancing its Trap and Target technology, aimed at intranasal delivery of active pharmaceutical ingredients for potential therapeutic use. Operating today from its headquarters in Raanana, Israel, and founded in 2005, the company occupies a niche at the intersection of medical devices and drug delivery systems, serving healthcare markets that seek non-systemic, preventive, and supportive nasal solutions for infectious disease exposure and allergy management.
CEO Mr. Tomer Izraeli · 2 employees · Israel · https://www.polyrizon-biotech.com